# Carter McNabb

> Carter McNabb is a Series D investor at RC Capital backing Health Care and Medical Device. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [RC Capital](https://shizune.co/investors/profile/river-cities-capital)
- Location: Cincinnati, United States
- Total investments: 20
- Last investment: May 2026
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/carter-mcnabb-3378b520/

Carter McNabb is a Series D investor at RC Capital in Cincinnati focused on Health Care and Medical Device. Carter McNabb joined River Cities Capital Funds in 1999 and leads the firm's healthcare investing practice with concentration on medical device and technology-enabled healthcare service companies. Carter previously worked at OrthoHelix as a Board. He attended Vanderbilt University - Owen Graduate School of Management and TrinityCollege-Hartford.Previously, Mr. McNabb worked in marketing and business development for Home Technology Healthcare, a comprehensive home healthcare company offering nursing, DME, infusion therapy and hospice across the southeast. Home Technology Healthcare was private equity financed by Willis Stein & Co. and acquired by Integrated Health Services in 1997. Carter worked in equity research at J.C. Bradford & Co. (now part of UBS) while attending business school at Vanderbilt University. He is a graduate of Trinity College in Hartford, CT. He has led over 14 healthcare investments for River Cities during his tenure and currently serves as Director on the boards of OrthoHelix Surgical Designs, OrthoScan, Nico Neuro, Health Integrated, AcceleCare Wound Centers, and SurgiQuest.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 65% |
| Medical Device | 9 | 45% |
| Medical | 8 | 40% |
| Biotechnology | 8 | 40% |
| Pharmaceutical | 3 | 15% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 6 | 30% |
| Series B | 3 | 15% |
| Series C | 3 | 15% |
| Venture - Series Unknown | 3 | 15% |
| Funding Round | 2 | 10% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Captive Radiology | Captive Radiology offers its services to hospitals and physician groups. They are laser-focused on maximizing the clinical, market, and financial potential of diagnostic imaging services. Their services include analysis, operations management, project management, radiology staffing, radiology equipment, accreditation, healthcare marketing, qualityassurance, and more. |  | Private Equity | May 22, 2026 |  |
| Catalyst OrthoScience | Catalyst OrthoScience is an early stage medical device company that is bringing the Catalyst CSR total shoulder to market. The CSR total shoulder is an innovative, streamlined solution that is associated with less stretching of the muscles and ligaments in order to place the implants. It is designed to be a more natural solution with a focus onrapid recovery for the patient. | $20M | Venture - Series Unknown | Sep 10, 2024 |  |
| NICO | NICO Corporation designs, develops, and markets medical devices for minimally invasive neurosurgery and skull base and spinal surgical procedures. The company offers NICO Myriad, a disposable non-heat generating neuro and spinal tissue and tumor resection device. NICO Corporation was founded in 2007 and is based in Indianapolis, Indiana. | $12.6M | Venture - Series Unknown | Oct 27, 2022 |  |
| Catalyst OrthoScience | Catalyst OrthoScience is an early stage medical device company that is bringing the Catalyst CSR total shoulder to market. The CSR total shoulder is an innovative, streamlined solution that is associated with less stretching of the muscles and ligaments in order to place the implants. It is designed to be a more natural solution with a focus onrapid recovery for the patient. | $12.3M | Series D | Oct 06, 2021 |  |
| Checkpoint Surgical | DRIVING INNOVATION IN NERVE SURGERY Checkpoint Surgical is at the forefront of advancements in peripheral nerve surgery. Checkpoint's portfolio features cutting-edge intraoperative nerve stimulation devices, innovative biomaterial implants, and specialized instruments for the meticulous craft of nerve and tendon surgery. | $16M | Venture - Series Unknown | Aug 24, 2021 |  |
| Q'Apel Medical | Q'Apel Medical designs access device technology for neurovascular interventions and unmet clinical needs. The company was founded in 2016 and is headquartered in Fremont, California. | $22M | Series C | Feb 11, 2021 |  |
| Bolder Surgical | Bolder Surgical exists to serve healthcare providers by developing precisely designed surgical instruments that allow access to confined and often delicate structures. By addressing this comparatively small market, they are able to meet the specific needs of surgeons and promote the advancement of surgical approaches that reach beyond whattraditional instruments have allowed. The company was founded in 2010 and is headquartered in Boulder, Colorado. | $27M | Series C | Jan 16, 2019 |  |
| Urgent Team Holdings, Inc. | Urgent Team Holdings, Inc. operates urgent care centers that provide urgent and primary health care services. It offers services for patients in the areas of sprains, strains, and broken bones; muscular pain and injuries; eye irritation and eye injuries; cuts and scrapes; bites, stings, and allergic reactions; burns and infections; diarrhea,nausea, and vomiting; flu, colds, and viral illnesses; pneumonia and bronchitis; and asthma attacks. The company also offers preventative screenings/wellness services, including flu shots, physicals, immunization and vaccinations, EKGs, and osteoporosis screening, as well as blood glucose, blood pressure, and cholesterol checks; radiology, lab work and diagnostic testing, and drug and alcohol screening services; and services for employers. | $18M | Series D | Oct 12, 2018 |  |
| OrthAlign | OrthAlign is a privately-held medical device company providing healthier and more pain-free lifestyles to joint replacement patients. The company is developing a line of computer-assisted surgical devices that distill the critical features and benefits of large surgical navigation systems. Its goal is to create a new standard of care in total jointreplacement, making consistent, and measurable results accessible to surgeons and patients.The company was founded in 2009 and based in Aliso Viejo, California. | $10M | Series D | Sep 27, 2017 |  |
| NICO | NICO Corporation designs, develops, and markets medical devices for minimally invasive neurosurgery and skull base and spinal surgical procedures. The company offers NICO Myriad, a disposable non-heat generating neuro and spinal tissue and tumor resection device. NICO Corporation was founded in 2007 and is based in Indianapolis, Indiana. | $15M |  | Feb 24, 2016 |  |

10 of 20 investments shown.

## Co-investors
- [Mutual Capital Partners](https://shizune.co/investors/profile/mutual-capital-partners-funds) — VC Fund, 6 deals together
- [California Technology Ventures](https://shizune.co/investors/profile/california-technology-ventures) — VC Fund, 3 deals together
- [Aphelion Capital](https://shizune.co/investors/profile/aphelion-capital) — VC Fund, 2 deals together
- [Ballast Point Ventures](https://shizune.co/investors/profile/ballast-point-ventures) — VC Fund, 2 deals together
- [JumpStart Inc.](https://shizune.co/investors/profile/jumpstartinc) — VC Fund, 2 deals together
- [Research Corporation Technologies](https://shizune.co/investors/profile/research-corporation-technologies) — VC Fund, 2 deals together

## About RC Capital

VC Fund · Cincinnati, United States

RCC is a growth equity firm building high-potential healthcare companies by leveraging the unique interplay of our segments of focus: medical device, healthcare services and healthcare IT. We are dedicated to investing on the right side of healthcare, growing companies that enable clinicians to improve the delivery of care and the experiences andoutcomes for patients. We seek to be a business partner first and a capital provider second, investing significant human capital to leverage our domain expertise, a network of healthcare thought leaders and deep relationships with health systems assembled over our 28-year history. With more than $900 million of capital raised and a consistent track record, the firm has established itself as a preferred source of growth capital.

5 contacts available at RC Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Midkiff | Principal | https://shizune.co/investors/profile/adam-midkiff |
| Adrienne Vannarsdall | CFO | https://shizune.co/investors/profile/adrienne-vannarsdall |
| Britney Hamberg | Vice President Marketing; Director of Operations and Communications | https://shizune.co/investors/profile/britney-grimmelsman |
| Carter McNabb | Managing Director | https://shizune.co/investors/profile/carter-mcnabb |
| Daniel T. Fleming | Managing Director | https://shizune.co/investors/profile/daniel-t-fleming |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Carter McNabb invest in?

Carter McNabb invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Carter McNabb last invest?

The most recent investment recorded for Carter McNabb closed in May 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co